GST Treatment of Medicines for Inpatients Explained
The taxation of healthcare services has always been a sensitive subject, balancing the need for revenue with the essential nature of medical care. A significant development in this area is the recent interim order by the Calcutta High Court in the case of Narayana Hrudayalaya. The core of the dispute revolves around the GST treatment of medicines for inpatients and whether the supply of drugs, consumables, and implants should be taxed separately or treated as part of an exempt composite healthcare service.
Composite Supply and Healthcare Exemptions under GST
Under the GST regime, healthcare services provided by a clinical establishment, an authorized medical practitioner, or para-medics are generally exempt from tax. However, hospitals often bill for various components separately, such as room rent, doctor consultations, and medicines. The critical question is whether these items constitute a ‘composite supply’.
A composite supply exists when two or more goods or services are naturally bundled and supplied in conjunction with each other in the ordinary course of business, where one is the principal supply. In the context of the GST treatment of medicines for inpatients, the principal supply is healthcare. If the administration of medicines and the use of implants are integral to the treatment provided to a patient admitted to the hospital, they should logically be bundled with the exempt healthcare service.
- Inpatients receive a comprehensive suite of services that cannot be unbundled without affecting the treatment.
- Medicines and consumables used during a procedure are not optional retail purchases for the patient.
- The healthcare exemption is intended to cover the entire ‘care’ package provided by the hospital.
The Impact of Section 76 and MRP Billing Practices
A major point of contention in the Narayana Hrudayalaya case is the application of Section 76 of the CGST Act. The tax authorities argued that because the hospital billed patients based on the Maximum Retail Price (MRP)—which often includes a profit margin—and did not specifically charge GST on the bill, any ‘excess’ collected could be viewed as GST that must be deposited with the government.
However, the Calcutta High Court’s interim stay suggests that GST treatment of medicines for inpatients cannot automatically be equated to GST collection simply because the billing is at MRP. If the underlying supply is exempt as part of a composite healthcare service, then the price charged (even if at MRP) does not inherently contain a tax element that the government can claim under Section 76. This section is typically invoked when an amount is collected ‘representing it as tax’, which is not necessarily the case in standard hospital billing for exempt services.
Distinction Between Inpatients and Outpatients
It is vital to distinguish between inpatients and outpatients (OPD). For outpatients, the supply of medicines from a hospital pharmacy is generally treated as a separate taxable supply of goods. The GST treatment of medicines for inpatients is different because the patient is under the continuous care of the hospital, making the medicine an inseparable part of the service delivery. This distinction is what provides the legal basis for the exemption of medicines supplied during hospitalization.
Implications for the Healthcare Industry
The Calcutta High Court’s intervention provides temporary relief and much-needed clarity for clinical establishments across India. If hospitals were forced to pay GST on medicines supplied to inpatients, it would significantly increase the cost of healthcare, as hospitals cannot claim Input Tax Credit (ITC) on exempt services. This would lead to a cascading effect, ultimately burdening the end consumer—the patient.
Tax professionals and hospital administrators must closely monitor the final outcome of this case. For now, the focus remains on ensuring that billing practices accurately reflect the nature of the composite supply to maintain the integrity of the healthcare exemption. Understanding the nuances of the GST treatment of medicines for inpatients is essential for compliance and financial planning in the medical sector.